Clyz Labs, a Manchester UK-based early-stage cancer diagnostics company, raised a seed funding of undisclosed amount.
Catapult Ventures made the investment through the GM&C Life Sciences Fund.
The company intends to use the funds to further optimize and validate the Cancertain™ Assay in patients with lung cancer and to generate much needed evidence in a clinical setting.
Founded in 2017 and led by Dr Himanshu Kataria, Director, Clyz is developing the Cancertain™ Assay as a service to select the best drug therapy for personalised cancer treatment. CLYZ Labs will combine information on drug sensitivity of the patient’s own tumor cells using innovative 3D Cell culture techniques along with biomarker and treatment guidelines to provide a personalised treatment recommendation.
The company is advancing the first clinical trial involving its test, which has already secured all regulatory approvals.